Athira Pharma Inc. (NASDAQ: ATHA) stock fell -4.42% on Wednesday to $3.03 against a previous-day closing price of $3.17. With 0.23 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.24 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.2000 whereas the lowest price it dropped to was $2.9900. The 52-week range on ATHA shows that it touched its highest point at $14.92 and its lowest point at $2.53 during that stretch. It currently has a 1-year price target of $11.75.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ATHA was down-trending over the past week, with a drop of -1.62%, but this was down by -10.88% over a month. Three-month performance dropped to -15.13% while six-month performance fell -65.99%. The stock lost -78.91% in the past year, while it has lost -76.75% so far this year. A look at the trailing 12-month EPS for ATHA yields -2.10 with Next year EPS estimates of -2.97. For the next quarter, that number is -0.67. This implies an EPS growth rate of -141.90% for this year and -22.20% for next year.
Float and Shares Shorts:
At present, 37.82 million ATHA shares are outstanding with a float of 35.89 million shares on hand for trading. On Oct 13, 2022, short shares totaled 1.83 million, which was 4.85% higher than short shares on Sep 14, 2022. In addition to Dr. Mark J. Litton M.B.A., MBA, Ph.D. as the firm’s Pres, CEO & Director, Ms. Rachel P. Lenington M.B.A. serves as its Chief Operating Officer.
Through their ownership of 64.06% of ATHA’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 44.83% of ATHA, in contrast to 14.20% held by mutual funds. Shares owned by individuals account for 14.11%. As the largest shareholder in ATHA with 12.69% of the stake, Perceptive Advisors LLC holds 4,797,278 shares worth 4,797,278. A second-largest stockholder of ATHA, BlackRock Fund Advisors, holds 2,367,438 shares, controlling over 6.26% of the firm’s shares. RA Capital Management LP is the third largest shareholder in ATHA, holding 1,878,000 shares or 4.97% stake. With a 3.13% stake in ATHA, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 1,183,657 shares are owned by the mutual fund manager. The iShares Russell 2000 ETF, which owns about 2.27% of ATHA stock, is the second-largest Mutual Fund holder. It holds 857,277 shares valued at 2.84 million. Vanguard Extended Market Index Fu holds 1.21% of the stake in ATHA, owning 458,537 shares worth 1.52 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ATHA since 6 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ATHA analysts setting a high price target of $33.00 and a low target of $3.00, the average target price over the next 12 months is $11.75. Based on these targets, ATHA could surge 989.11% to reach the target high and fall by -0.99% to reach the target low. Reaching the average price target will result in a growth of 287.79% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ATHA will report FY 2022 earnings on 03/23/2023. Analysts have provided yearly estimates in a range of -$2.30 being high and -$2.47 being low. For ATHA, this leads to a yearly average estimate of -$2.41. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Athira Pharma Inc. surprised analysts by $0.11 when it reported -$0.53 EPS against a consensus estimate of -$0.64. The surprise factor in the prior quarter was -$0.01. Based on analyst estimates, the high estimate for the next quarter is -$0.57 and the low estimate is -$0.71. The average estimate for the next quarter is thus -$0.65.
Summary of Insider Activity:
Insiders traded ATHA stock several times over the past three months with 2 Buys and 0 Sells. In these transactions, 11,581 shares were bought while 0 shares were sold. The number of buy transactions has increased to 21 while that of sell transactions has risen to 5 over the past year. The total number of shares bought during that period was 1,493,716 while 19,995 shares were sold.